- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
IRCM Breakthrough Could Lead to a Drug for a Rare Disease
Institut de recherches cliniques de Montréal (IRCM) reported that A drug candidate discovered by Peter W. Schiller, Director of the Chemical Biology and Peptide Research unit at IRCM and Research Professor in the Department of Pharmacology of the Université de Montréal, has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of primary mitochondrial myopathy. The candidate, elamipretide (formerly known as Bendavia), is being developed by Stealth BioTherapeutics Inc.
Institut de recherches cliniques de Montréal (IRCM) reported that A drug candidate discovered by Peter W. Schiller, Director of the Chemical Biology and Peptide Research unit at IRCM and Research Professor in the Department of Pharmacology of the Université de Montréal, has been granted Fast Track designation by the Food and Drug Administration (FDA) for the treatment of primary mitochondrial myopathy. The candidate, elamipretide (formerly known as Bendavia), is being developed by Stealth BioTherapeutics Inc.
According to the press release:
Primary mitochondrial myopathy is a type of rare genetic disorder that impairs patient health and well-being. The muscle weakness and extraordinary fatigue experienced by people suffering from this disease make simple daily tasks very challenging. There is currently no FDA-approved treatment for these patients. Peter Schiller, in collaboration with Professor Hazel Szeto, of Cornell University, discovered a family of molecules, among which is elamipretide.
Peter Schiller commented:
Due to this property, elamipretide could become the first treatment designed for primary mitochondrial myopathy. The FDA’s grant of a Fast Track designation for this treatment is therefore excellent news.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.